A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2018
At a glance
- Drugs HTI immunogen (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms AELIX-002
- Sponsors Aelix Therapeutics
- 20 Mar 2018 Planned number of patients changed from 15 to 45.
- 20 Mar 2018 Planned End Date changed from 1 May 2018 to 31 Jan 2020.
- 20 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 30 Jun 2019.